Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.50 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23221311 | 0.84 | NPC1 (0.52) | MAPTNPC1RAB9ACNR1CNR2 | |
| SCHEMBL30672320 | 0.81 | APLNR (0.52) | MAPTNPC1RAB9ACLK4KMT2A | |
| SCHEMBL26663295 | 0.81 | APLNR (0.52) | MAPTNPC1RAB9ACLK4KMT2A | |
| SCHEMBL21805769 | 0.77 | NPC1 (0.61) | MAPTNPC1RAB9ACLK4VNN1 | |
| SCHEMBL16290847 | 0.75 | NPC1 (0.58) | MAPTNPC1RAB9ACLK4KMT2A | |
| SCHEMBL29889719 | 0.75 | NPC1 (0.58) | MAPTNPC1RAB9ACLK4KMT2A | |
| SCHEMBL24460958 | 0.75 | CLK4 (0.53) | MAPTNPC1RAB9ACLK4HTT | |
| SCHEMBL17376450 | 0.74 | CNR1 (0.46) | MAPTNPC1RAB9ACNR1CNR2 | |
| SCHEMBL14330643 | 0.74 | CLK4 (0.56) | MAPTNPC1RAB9ACLK4VNN1 | |
| SCHEMBL847193 | 0.74 | ADRB1 (0.50) | MAPTNPC1RAB9AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| CN-109803963-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2018065768-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | MAPT 3724/4885NPC1 3116/4885RAB9A 3037/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | MAPT 3724/4885NPC1 3116/4885RAB9A 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.